<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902023000101203</article-id>
<article-id pub-id-type="doi">10.29193/rmu.39.1.3</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Uso ambulatorio de medicamentos potencialmente inapropiados en adultos mayores usuarios de la RAP Metropolitana de ASSE durante 2019]]></article-title>
<article-title xml:lang="en"><![CDATA[Potentially inappropriate medication use in older adults assisted as outpatients in ASSE&#8217;s Metropolitan RAP (Primary Health Care) during 2019]]></article-title>
<article-title xml:lang="pt"><![CDATA[Uso ambulatorial de medicamentos potencialmente inapropriados em idosos usuários da RAPE Metropolitana da ASSE durante 2019]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabral]]></surname>
<given-names><![CDATA[Santiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jara]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Goyret]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fabbiani]]></surname>
<given-names><![CDATA[Stefano]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garafoni]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Edelman]]></surname>
<given-names><![CDATA[Alex]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,UDELAR Facultad de Medicina Departamento de Farmacología y Terapéutica]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,UDELAR Facultad de Medicina Departamento de Farmacología y Terapéutica]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,UDELAR Facultad de Medicina Departamento de Farmacología y Terapéutica]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>39</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902023000101203&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902023000101203&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902023000101203&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  los adultos mayores son una población de riesgo para el desarrollo de reacciones adversas a los medicamentos. Los medicamentos potencialmente inapropiados son aquellos que representan mayores riesgos que beneficios en este grupo etario. Se cuenta con herramientas de apoyo a la prescripción en geriatría que permiten identificar a estos medicamentos y mediante la aplicación de estudios de utilización de medicamentos, podemos describir o analizar el uso de los mismos en una población.  Objetivos:  reconocer disponibilidad de medicamentos potencialmente inapropiados para adultos mayores en la RAP metropolitana de ASSE durante 2019 y establecer un diagnóstico de situación de consumo de los mismos durante ese año.  Método:  se realizó un análisis del vademécum institucional mediante la aplicación de los Criterios de Beers 2019 y dos escalas de riesgo anticolinérgico para identificar medicamentos potencialmente inapropiados. Posteriormente se realizó un estudio de utilización de los medicamentos identificados, mediante datos de dispensación de farmacia entre el 1 de enero y 31 de diciembre de 2019. El consumo se expresó en Dosis Diarias Definidas por cada 1000 adultos mayores-año (DHD).  Resultados:  se identificaron 16 medicamentos potencialmente inapropiados, de los cuales los más usados fueron clonazepam (DHD 69), quetiapina (65,6), alprazolam (DHD 43,7), flunitrazepam (DHD 42,7) y zolpidem (DHD 36,4).  Conclusiones:  la aplicación de herramientas explícitas facilita la identificación de medicamentos potencialmente inapropiados para adultos mayores y se evidenció un consumo elevado de los mismos durante el año 2019 a expensas de derivados benzodiazepínicos y quetiapina.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  older adults are at higher risk for developing adverse drug reactions. Potentially inappropriate medications are drugs that have more risks than benefits in this age group. There are a number of tools to support the prescription of medication in geriatrics that allow the identification of these medications, and by applying studies developed on the use of medications we may describe or analyze their impact on a given population.  Objectives:  to recognize availability of potentially inappropriate medications in older adults in ASSE&#8217;s Metropolitan RAP during 2019 and to draw conclusions about the current situation in terms of the consumption of this kind of medications.  Method:  an institutional analysis of medications available in each healthcare provided was conducted through the application of Beers Criteria 2019, and two anticholinergic risk scales were used to identify potentially inappropriate medications. Subsequently, the use of the medications identified was studied by applying pharmacy dispensing data between January 1 and December 31, 2019. Consumption was expressed in defined daily doses every 1000 adults per year (DHD).  Results:  16 potentially inappropriate medications were identified, the most widely used of which were clonazepam (DHD 69), quetiapine (65.6), alprazolam (DHD 43.7), flunitrazepam (DHD 42.7) and zolpidem (DHD 36.4). Conclusions: Applying explicit tools makes it easier to identify potentially inappropriate medications for older adults. An increased consumption of these kinds of drugs was noticed during 2019, as a result of benzodiazepine derivatives and quetiapine.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  os idosos são uma população de risco para o desenvolvimento de reações adversas a medicamentos. Medicamentos potencialmente inapropriados são aqueles que apresentam maiores riscos do que benefícios nessa faixa etária. Existem ferramentas de apoio à prescrição em geriatria que permitem identificar esses medicamentos e, por meio da aplicação de estudos de utilização de medicamentos, descrever ou analisar seu uso em uma população.  Objetivos:  reconhecer a disponibilidade de medicamentos potencialmente inapropriados para idosos na RAP metropolitana da ASSE durante o ano de 2019 e estabelecer um diagnóstico de consumo durante esse ano.  Método:  o formulário institucional foi analisado utilizando os Critérios de Beers 2019 e duas escalas de risco anticolinérgico para identificar medicamentos potencialmente inapropriados. Posteriormente, foi realizado um estudo de consumo dos medicamentos identificados, através dos dados de dispensação da farmácia entre 1 de janeiro e 31 de dezembro de 2019. O consumo foi expresso em Doses Diárias Definidas por 1000 idosos-ano (DHD).  Resultados:  foram identificados 16 medicamentos potencialmente inapropriados, sendo clonazepam (DHD 69), quetiapina (65,6), alprazolam (DHD 43,7), flunitrazepam (DHD 42,7) e zolpidem (DHD 36,4) os mais utilizados  Conclusões:  a aplicação de ferramentas explícitas facilita a identificação de medicamentos potencialmente inapropriados para idosos; foi observado um alto consumo dos mesmos em detrimento dos derivados benzodiazepínicos e da quetiapina durante o período do estudo.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Utilización de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Anciano]]></kwd>
<kwd lng="es"><![CDATA[Anciano de 80 o más años]]></kwd>
<kwd lng="es"><![CDATA[Hipnóticos y sedantes]]></kwd>
<kwd lng="es"><![CDATA[Antipsicóticos]]></kwd>
<kwd lng="es"><![CDATA[Benzodiazepinas]]></kwd>
<kwd lng="es"><![CDATA[Estudios epidemiológicos]]></kwd>
<kwd lng="en"><![CDATA[Drug utilization]]></kwd>
<kwd lng="en"><![CDATA[Aged]]></kwd>
<kwd lng="en"><![CDATA[Aged, 80 and over]]></kwd>
<kwd lng="en"><![CDATA[Hypnotics and sedatives]]></kwd>
<kwd lng="en"><![CDATA[Antipsychotic agents]]></kwd>
<kwd lng="en"><![CDATA[Benzodiazepines]]></kwd>
<kwd lng="en"><![CDATA[Epidemiologic studies]]></kwd>
<kwd lng="pt"><![CDATA[Uso de medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[Idoso]]></kwd>
<kwd lng="pt"><![CDATA[Idoso de 80 anos ou mais]]></kwd>
<kwd lng="pt"><![CDATA[Hipnóticos e sedativos]]></kwd>
<kwd lng="pt"><![CDATA[Antipsicóticos]]></kwd>
<kwd lng="pt"><![CDATA[Benzodiazepinas]]></kwd>
<kwd lng="pt"><![CDATA[Estudos epidemiológicos]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Uruguay. Parlamento del Uruguay. Cámara de Representantes</collab>
<article-title xml:lang=""><![CDATA[Proyecto de Ley. ADULTO MAYOR. CODIGO. APROBACION. Asunto: 133330]]></article-title>
<source><![CDATA[]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarkar]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maselli]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzales]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug events in U S. adult ambulatory medical care]]></article-title>
<source><![CDATA[Health Serv Res]]></source>
<year>2011</year>
<volume>46</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1517-33</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vilosio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Saimovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización de los criterios STOPP-START una herramienta para la detección de medicación potencialmente inadecuada en ancianos]]></article-title>
<source><![CDATA[Evidencia]]></source>
<year>2015</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>124-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danza]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Branco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López Pampín]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Agorio]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Caleri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Patiño]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benzodiazepinas y fractura de cadera: estudio de casos y controles.]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2015</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>120-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruxton]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Woodman]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mangoni]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2015</year>
<volume>80</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>209-20</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Dublin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hanlon]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Hubbard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cumulative use of strong anticholinergics and incident dementia a prospective cohort study]]></article-title>
<source><![CDATA[JAMA Intern Med]]></source>
<year>2015</year>
<volume>175</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>401-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Uruguay. Instituto Nacional de Estadística</collab>
<source><![CDATA[Censo 2011]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>By the 2019 American Geriatrics Society Beers Criteria(r) Update Expert Panel</collab>
<article-title xml:lang=""><![CDATA[American Geriatrics Society 2019 updated AGS Beers Criteria(r) for potentially inappropriate medication use in older adults]]></article-title>
<source><![CDATA[J Am Geriatr Soc]]></source>
<year>2019</year>
<volume>67</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>674-94</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Passi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Margozzini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hoyl]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Carrasco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso inapropiado de medicamentos en adultos mayores resultados de la Encuesta Nacional de Salud 2010]]></article-title>
<source><![CDATA[Rev Méd Chile]]></source>
<year>2016</year>
<volume>144</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>417-25</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fajreldines]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Insua]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schnitzler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de prescripción potencialmente inapropiada de medicamentos en adultos mayores]]></article-title>
<source><![CDATA[Rev Calid Asist]]></source>
<year>2016</year>
<volume>31</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>279-84</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<collab>De la Calle B.Pérez ME.Romero M.García E.Berrocal MA</collab>
<article-title xml:lang=""><![CDATA[Carga anticolinérgica aspectos a considerar]]></article-title>
<source><![CDATA[Bol Farmacot Castilla-La Mancha]]></source>
<year>2018</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boustani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Munger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maidment]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of anticholinergics on the aging brain a review and practical application]]></article-title>
<source><![CDATA[Aging Health]]></source>
<year>2008</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>311-20</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rudolph]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Salow]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Angelini]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[McGlinchey]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The anticholinergic risk scale and anticholinergic adverse effects in older persons]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2008</year>
<volume>168</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>508-13</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pasina]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Colzani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cortesi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tettamanti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zambon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nobili]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relation between delirium and anticholinergic drug burden in a cohort of hospitalized older patients an observational study]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2018</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>85-91</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gamble]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Luben]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Wareham]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Khaw]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Myint]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baseline anticholinergic burden from medications predicts fatal and non-fatal stroke in the EPIC-Norfolk general population]]></article-title>
<source><![CDATA[Int J Epidemiol]]></source>
<year>2018</year>
<volume>47</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>625-33</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Figueras]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vallano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Narvaéz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Fundamentos metodológicos de los EUM: una aproximación práctica para estudios en ámbito hospitalario]]></source>
<year>2003</year>
<publisher-loc><![CDATA[Managua ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud de Nicaragua]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laporte]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Tognoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Principios de epidemiología del medicamento]]></source>
<year>1993</year>
<edition>2</edition>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Masson Salvat]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Speranza]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pagano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Artagaveytia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Olmos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Toledo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumo de benzodiazepinas en la población uruguaya: un posible problema de salud pública]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2015</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>112-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Olmos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Toledo]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución del consumo de antipsicóticos en la Policlínica Psiquiátrica del Hospital Vilardebó]]></article-title>
<source><![CDATA[Rev Psiquiatr Urug]]></source>
<year>2017</year>
<volume>81</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>106-12</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pagano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Speranza]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del consumo en antidepresivos en la población uruguaya entre 2010 y 2014]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2021</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<collab>Uruguay. Administración de los Servicios de Salud del Estado</collab>
<source><![CDATA[Centro Nacional de Afiliados de ASSE.]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>Aging Brain Program</collab>
<source><![CDATA[Anticholinergic Cognitive Burden Scale 2012 Update]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rudolph]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Salow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Angelini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McGlinchey]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[McGlinchey]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2008</year>
<volume>168</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>508-13</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<collab>Uruguay. Ministerio de Salud Pública</collab>
<source><![CDATA[Indicadores de desempeño asistencial]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<collab>WHO Collaborating Centre for Drug Statistics Methodology</collab>
<source><![CDATA[International language for drug utilization research]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Misa]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Utilización de benzodiacepinas en el adulto mayor de la Red de Atención Primaria Metropolitana de ASSE. (Trabajos realizados en el marco del residentado del Diploma de Especialista en Farmacia Hospitaria, Facultad de Química, UdelaR)]]></source>
<year>2018</year>
<conf-name><![CDATA[ XII Jornadas Académicas del Diploma de Especialista en Farmacia Hospitalaria]]></conf-name>
<conf-date>2018</conf-date>
<conf-loc>Montevideo </conf-loc>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qualgia]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Paciaroni]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Elías]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Leiva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumo de benzodiacepinas en una comuna de la región metropolitana de Rosario, provincia de Santa Fe, Argentina]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2009</year>
<volume>41</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>520-1</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabaleiro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Corrales]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipsicóticos para el tratamiento de síntomas del comportamiento en las demencias]]></article-title>
<source><![CDATA[Bol Ter Andal]]></source>
<year>2018</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>20-7</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hálfdánarson]]></surname>
<given-names><![CDATA[Ó]]></given-names>
</name>
<name>
<surname><![CDATA[Zoëga]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Aagaard]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bernardo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brandt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fusté]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International trends in antipsychotic use a study in 16 countries, 2005-2014]]></article-title>
<source><![CDATA[Eur Neuropsychopharmacol]]></source>
<year>2017</year>
<volume>27</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1064-76</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
